報價延遲最少15分鐘:2024/06/21 01:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.88 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.24/-3.22
|
|
企業價值
541.20M
|
| 資產負債 |
|
每股賬面淨值
6.10
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/21 01:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |